

15 October 2020

The Manager Companies
ASX Limited
20 Bridge Street
SYDNEY NSW 2000

(2 pages by email)

Dear Madam,

BIT225 HIV-1 IMMUNOMODULATORY PAPER PUBLISHED

- Key data from Biotron's Phase 2 trial published in prestigious international scientific journal.
- Phase 2 trial data shows BIT225 induces immunomodulation effects and improves key marker of health outcomes in combination with antiretroviral treatment.

The Directors of Biotron Limited ('Biotron') are pleased to advise that a manuscript containing data from its Phase 2 trial of BIT225 in HIV-1-infected subjects has been accepted and published in a prestigious international journal.

The peer-reviewed paper, entitled "Human immunodeficiency virus type-1 Vpu inhibitor, BIT225, in combination with 3-drug antiretroviral therapy modulates inflammation and immune cell function" has been published online as advance access in the Journal of Infectious Diseases.

As previously advised to the market (refer BIT ASX announcement 12/3/20), the Phase 2 clinical trial demonstrated that BIT225 induced statistically significant changes to key immune cell populations. These changes had not previously been reported for any HIV-1 therapeutics. The results open the possibility that BIT225 may play a key role in restoring immune functions leading to improved health outcomes and elimination of residual virus.


Biotron is currently mapping out the next stage of clinical development of this important new anti-HIV class of compounds in consultation with the Company's Chief Medical Officer and international Scientific Advisory Board.

The recent completion of long-term toxicology studies of BIT225 is an important milestone as they support long-term dosing of BIT225 in the next stage of clinical development and beyond.

A copy of the manuscript can be viewed via a link on the Biotron website homepage - www.biotron.com.au.

This announcement has been approved by the Board of Biotron Limited.

Yours sincerely



Peter J. Nightingale
Company Secretary

pjn10529

About Biotron

Biotron Limited is engaged in the research, development, and commercialisation of drugs targeting significant viral diseases with unmet medical need. The Company has BIT225 in clinical development for HIV-1 and a promising preclinical program for HBV. In addition, Biotron has several earlier stage programs designing drugs that target a class of virus protein known as viroporins which have a key role in the virus life cycle of a very broad range of viruses, many of which have caused worldwide health issues such as Coronavirus, Dengue, Ebola, Middle East Respiratory virus, Influenza and Zika viruses.

Enquiries

Dr Michelle Miller
Managing Director
Biotron Limited
+61-(0)412313329

Rudi Michelson
Monsoon Communications
+61-3 9620 3333